Nanna Lüneborg PhD, MBA
General Partner
Capstan’s mission is to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA-based therapies.
Capstan Therapeutics' core platform technology pertains to proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody, and are designed to deliver payloads, including mRNA or gene editing tools, capable of reprograming specific cell types in vivo.
The company's in vivo engineering technology has the potential to generate transformative therapies with applications possible across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.
Industry
Biotech
Status
Past
Location
US
Capstan was forging a new treatment modality that did not come with a navigation system. It took all of us, the team, our founders, and our investors, to sail through bumpy waters and find smoother seas!Laura Shawver
CEO of Capstan Therapeutics
